Related Experiment Video
Updated: Jun 10, 2026
05:45
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Emerging drugs for alpha-1-antitrypsin deficiency
1University of Birmingham, Queen Elizabeth Hospital, Department of Medical Sciences, Edgbaston, Birmingham, B15 2TH, UK. rob.stockley@uhb.nhs.uk
Expert Opinion on Emerging Drugs
|August 19, 2010
Summary
Alpha-1-antitrypsin (A1AT) deficiency causes chronic obstructive pulmonary disease (COPD) due to uncontrolled enzymes. New strategies aim to protect lungs and liver, but require careful evaluation.
Area of Science:
- Pulmonary Medicine
- Genetics
- Enzymology
Background:
- Alpha-1-antitrypsin (A1AT) deficiency is a genetic disorder linked to chronic obstructive pulmonary disease (COPD).
- Neutrophil-derived proteolytic enzymes cause lung damage in A1AT deficiency when A1AT cannot inhibit them.
- The Pi Z genetic variant leads to A1AT accumulation in the liver, causing liver disease.
Purpose of the Study:
- To review the pathophysiology of lung disease in A1AT deficiency.
- To present evidence for current and developing therapies for A1AT deficiency.
- To explore strategies for preventing lung and liver disease in A1AT deficiency.
Main Methods:
- Literature review focusing on the history and pathophysiology of A1AT deficiency.
- Analysis of evidence for existing therapies.
- Examination of preliminary and experimental strategies under development.
Main Results:
- A1AT deficiency serves as a model for understanding COPD pathophysiology, particularly the role of proteinases.
- Augmentation therapy shows efficacy in ameliorating disease progression.
- Emerging strategies focus on rebalancing proteinase activity and repairing lung damage.
Conclusions:
- A1AT deficiency is a valuable model for studying inflammation and proteolysis in COPD.
- Augmentation therapy is effective but costly; newer strategies require careful safety and efficacy assessment.
- Clinical trials for A1AT deficiency therapies face challenges due to patient numbers and outcome sensitivity.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...